AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$BLTE

Lin Yu-Hsin sold $19.1M of BLTE

Lin Yu-Hsin (Chief Executive Officer) sold 100,435 shares of BELITE BIO, INC (BLTE) at an average of $190.00 ($180.29–$198.09, $19.08M total) across 19 trades over 2026-09-04 to 2026-09-08 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Lin Yu-Hsin
Published Sep 9, 2026, 11:39 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 10, 2026, 12:04 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$BLTE
Bearish
medium confidence
Mentioned
$BLTE
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLTEBearishMed
01

Why it matters

The disclosed sale adds supply pressure and may influence short‑term price action.

02

Market read

Primary insider sell for a micro‑cap biotech; relevant for traders monitoring insider activity and biotech sector sentiment.

03

What to watch

Potential upcoming financing round or clinical trial news could offset sell pressure.

Relevance 6/10Novelty 7/10Timing: filing today

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$BLTEBearishMedium confidence
Context

CEO Lin Yu-Hsin sold 100,435 shares for $19.1M via a 10b5‑1 plan, reducing his stake to 70,134 shares.

Expected impact

Potential modest decline of 2‑4% over the next few days as the market digests the sale.

Evidence & confidence

The sale size is material for a micro‑cap biotech and was executed through a pre‑arranged plan, suggesting a planned liquidity event rather than panic, but still adds supply pressure.

Market effects

Sector

May raise scrutiny on biotech insider activity, prompting investors to watch other micro‑cap biotech insiders.

Regional

Limited to U.S. biotech investors; no broader regional effect.

Global

Low global relevance beyond niche biotech community.

Counterpoint

What could challenge this read

The 10b5‑1 plan indicates a routine liquidity event; the sale may not reflect negative fundamentals.

Key entities

  • person
    Lin Yu-Hsin

    Chief Executive Officer of Belite Bio, Inc.

  • company
    Belite Bio, Inc.

    Biotech firm focused on gene‑editing therapies.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BLTE insider trading history →

Related articles

$BLTEHighAI 8/10

Belite Bio Says Nasdaq Approved Move to Higher Listing Tier

Belite Bio (BLTE) announced its approval to move to Nasdaq's Global Select Market, starting Oct. 19. The company expects increased institutional investor attention and improved liquidity. Belite Bio is seeking approval for tinlarebant, its lead treatment for Stargardt disease, with the FDA setting a Feb. 12, 2027, action date.

econotimes.com
$BLTEMed

Belite Bio stock price target maintained at $245 by H.C. Wainwright

H.C. Wainwright maintained a $245 price target for Belite Bio (BLTE) after regulatory submissions in three countries. The stock is up 88% over the past year, with analysts showing strong optimism. Belite Bio submitted applications for tinlarebant, a treatment for Stargardt disease type 1, in Singapore, the UK, and Switzerland. The company aims for a global launch, with a first-mover advantage if approved.

investing.com
$BLTEMedAI 8/10

Belite Bio submits drug applications in Singapore, UK, Switzerland

Belite Bio (BLTE) submitted Marketing Authorization Applications for tinlarebant, a treatment for Stargardt disease type 1, in Singapore, the UK, and Switzerland. The company also filed applications in the US and Japan, with the US application receiving Priority Review. Tinlarebant met its primary endpoint in a Phase 3 trial and has received several regulatory designations.

investing.com